Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia

5-Year results of a prospective, randomized, multicenter clinical trial

Brian Hill, William Belville, Reginald Bruskewitz, Muta Issa, Ramon Perez-Marrero, Claus Roehrborn, Martha Kennedy Terris, Michael Naslund

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Purpose: We report the 5-year efficacy and safety of transurethral needle ablation of the prostate (TUNA) compared to transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Materials and Methods: A total of 121 men 50 years or older with LUTS secondary to BPH a minimum of 3 months in duration were enrolled in this prospective, randomized clinical trial at 7 medical centers across the United States. Of the participants 65 (54%) were randomly selected to receive TUNA and 56 (46%) were selected to receive TURP. International Prostate Symptom Score, quality of life, peak urinary flow rate, post-void residual urinary volume, and prostate size and configuration were evaluated before the procedure and then annually for 5 years after the procedure. Adverse events were also recorded throughout the study. Results: Improvement from baseline for TUNA and TURP retained statistical significance at each interval for International Prostate Symptom Score, quality of life and peak flow rate. Post-void residual volume was statistically significant at all time points for TURP and at year 5 for TUNA. The TURP group reported 41% retrograde ejaculation, while the TUNA group reported none. The incident of erectile dysfunction, incontinence and stricture formation was also greater in TURP than in TUNA cases with significantly fewer adverse events for TUNA than for TURP. Conclusions: The results of this study demonstrate stable treatment outcomes after 5 years of followup and suggest that TUNA is an attractive treatment option for men with LUTS due to BPH.

Original languageEnglish (US)
Pages (from-to)2336-2340
Number of pages5
JournalJournal of Urology
Volume171
Issue number6 I
DOIs
StatePublished - Jan 1 2004
Externally publishedYes

Fingerprint

Transurethral Resection of Prostate
Prostatic Hyperplasia
Multicenter Studies
Needles
Randomized Controlled Trials
Therapeutics
Lower Urinary Tract Symptoms
Prostate
Residual Volume
Quality of Life
Ejaculation
Erectile Dysfunction

Keywords

  • Prostate
  • Prostatic hyperplasia
  • Transurethral resection of prostate
  • Urinary tract

ASJC Scopus subject areas

  • Urology

Cite this

Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia : 5-Year results of a prospective, randomized, multicenter clinical trial. / Hill, Brian; Belville, William; Bruskewitz, Reginald; Issa, Muta; Perez-Marrero, Ramon; Roehrborn, Claus; Terris, Martha Kennedy; Naslund, Michael.

In: Journal of Urology, Vol. 171, No. 6 I, 01.01.2004, p. 2336-2340.

Research output: Contribution to journalArticle

Hill, Brian ; Belville, William ; Bruskewitz, Reginald ; Issa, Muta ; Perez-Marrero, Ramon ; Roehrborn, Claus ; Terris, Martha Kennedy ; Naslund, Michael. / Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia : 5-Year results of a prospective, randomized, multicenter clinical trial. In: Journal of Urology. 2004 ; Vol. 171, No. 6 I. pp. 2336-2340.
@article{6f444d82d9304e738641f6729457f5c8,
title = "Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-Year results of a prospective, randomized, multicenter clinical trial",
abstract = "Purpose: We report the 5-year efficacy and safety of transurethral needle ablation of the prostate (TUNA) compared to transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Materials and Methods: A total of 121 men 50 years or older with LUTS secondary to BPH a minimum of 3 months in duration were enrolled in this prospective, randomized clinical trial at 7 medical centers across the United States. Of the participants 65 (54{\%}) were randomly selected to receive TUNA and 56 (46{\%}) were selected to receive TURP. International Prostate Symptom Score, quality of life, peak urinary flow rate, post-void residual urinary volume, and prostate size and configuration were evaluated before the procedure and then annually for 5 years after the procedure. Adverse events were also recorded throughout the study. Results: Improvement from baseline for TUNA and TURP retained statistical significance at each interval for International Prostate Symptom Score, quality of life and peak flow rate. Post-void residual volume was statistically significant at all time points for TURP and at year 5 for TUNA. The TURP group reported 41{\%} retrograde ejaculation, while the TUNA group reported none. The incident of erectile dysfunction, incontinence and stricture formation was also greater in TURP than in TUNA cases with significantly fewer adverse events for TUNA than for TURP. Conclusions: The results of this study demonstrate stable treatment outcomes after 5 years of followup and suggest that TUNA is an attractive treatment option for men with LUTS due to BPH.",
keywords = "Prostate, Prostatic hyperplasia, Transurethral resection of prostate, Urinary tract",
author = "Brian Hill and William Belville and Reginald Bruskewitz and Muta Issa and Ramon Perez-Marrero and Claus Roehrborn and Terris, {Martha Kennedy} and Michael Naslund",
year = "2004",
month = "1",
day = "1",
doi = "10.1097/01.ju.0000127761.87421.a0",
language = "English (US)",
volume = "171",
pages = "2336--2340",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6 I",

}

TY - JOUR

T1 - Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia

T2 - 5-Year results of a prospective, randomized, multicenter clinical trial

AU - Hill, Brian

AU - Belville, William

AU - Bruskewitz, Reginald

AU - Issa, Muta

AU - Perez-Marrero, Ramon

AU - Roehrborn, Claus

AU - Terris, Martha Kennedy

AU - Naslund, Michael

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Purpose: We report the 5-year efficacy and safety of transurethral needle ablation of the prostate (TUNA) compared to transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Materials and Methods: A total of 121 men 50 years or older with LUTS secondary to BPH a minimum of 3 months in duration were enrolled in this prospective, randomized clinical trial at 7 medical centers across the United States. Of the participants 65 (54%) were randomly selected to receive TUNA and 56 (46%) were selected to receive TURP. International Prostate Symptom Score, quality of life, peak urinary flow rate, post-void residual urinary volume, and prostate size and configuration were evaluated before the procedure and then annually for 5 years after the procedure. Adverse events were also recorded throughout the study. Results: Improvement from baseline for TUNA and TURP retained statistical significance at each interval for International Prostate Symptom Score, quality of life and peak flow rate. Post-void residual volume was statistically significant at all time points for TURP and at year 5 for TUNA. The TURP group reported 41% retrograde ejaculation, while the TUNA group reported none. The incident of erectile dysfunction, incontinence and stricture formation was also greater in TURP than in TUNA cases with significantly fewer adverse events for TUNA than for TURP. Conclusions: The results of this study demonstrate stable treatment outcomes after 5 years of followup and suggest that TUNA is an attractive treatment option for men with LUTS due to BPH.

AB - Purpose: We report the 5-year efficacy and safety of transurethral needle ablation of the prostate (TUNA) compared to transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Materials and Methods: A total of 121 men 50 years or older with LUTS secondary to BPH a minimum of 3 months in duration were enrolled in this prospective, randomized clinical trial at 7 medical centers across the United States. Of the participants 65 (54%) were randomly selected to receive TUNA and 56 (46%) were selected to receive TURP. International Prostate Symptom Score, quality of life, peak urinary flow rate, post-void residual urinary volume, and prostate size and configuration were evaluated before the procedure and then annually for 5 years after the procedure. Adverse events were also recorded throughout the study. Results: Improvement from baseline for TUNA and TURP retained statistical significance at each interval for International Prostate Symptom Score, quality of life and peak flow rate. Post-void residual volume was statistically significant at all time points for TURP and at year 5 for TUNA. The TURP group reported 41% retrograde ejaculation, while the TUNA group reported none. The incident of erectile dysfunction, incontinence and stricture formation was also greater in TURP than in TUNA cases with significantly fewer adverse events for TUNA than for TURP. Conclusions: The results of this study demonstrate stable treatment outcomes after 5 years of followup and suggest that TUNA is an attractive treatment option for men with LUTS due to BPH.

KW - Prostate

KW - Prostatic hyperplasia

KW - Transurethral resection of prostate

KW - Urinary tract

UR - http://www.scopus.com/inward/record.url?scp=2442614893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442614893&partnerID=8YFLogxK

U2 - 10.1097/01.ju.0000127761.87421.a0

DO - 10.1097/01.ju.0000127761.87421.a0

M3 - Article

VL - 171

SP - 2336

EP - 2340

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6 I

ER -